1-2 of 2
Denis Alferez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C135: AZ’4425 is a potent, selective, and orally bio-available progesterone receptor antagonist that has shown anti-tumor activity and inhibition of cancer stem cell proliferation.

Christine M. Chresta, Denis Alferez, Georgia Cerillo, Emma Still, Adina Hughes, Graeme Walker, Jane Kendrew, Claire Sadler, Jayne Harris, Iain Simpson, Andrew P. Thomas, Al Rabow, Robert Clarke, Sacha Howell, Graham Richmond
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C135.
https://doi.org/10.1158/1535-7163.TARG-13-C135
Published: 01 November 2013
View article titled, Abstract C135: AZ’4425 is a potent, selective, and orally bio-available progesterone receptor antagonist that has shown anti-tumor activity and inhibition of cancer stem cell proliferation.
Journal Articles

Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice

Denis Alferez, Robert W. Wilkinson, Jim Watkins, Richard Poulsom, Nikki Mandir, Stephen R. Wedge, Ian T. Pyrah, Neil R. Smith, Lynsay Jackson, Anderson J. Ryan, Robert A. Goodlad
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (3): 590–598.
https://doi.org/10.1158/1535-7163.MCT-07-0433
Published: 17 March 2008
View article titled, Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in <em>Apc</em><sup>Min/+</sup> mice
Open the PDF for Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in <em>Apc</em><sup>Min/+</sup> mice in another window